




PHARMACEUTICAL 2023

Inozyme Pharma Inc.
Rank 132 of 446





PHARMACEUTICAL 2023

Inozyme Pharma Inc.
Rank 132 of 446

The relative strengths and weaknesses of Inozyme Pharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Inozyme Pharma Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 91% points. The greatest weakness of Inozyme Pharma Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 20% points.

The company's Economic Capital Ratio, given in the ranking table, is 171%, being 127% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	131,393
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	14,715
Liabilities, Non-Current	1,947
Other Assets	5,784
Other Compr. Net Income	-223
Other Expenses	0
Other Liabilities	4,139
Other Net Income	1,614
Other Revenues	0
Property and Equipment	2,018
Research and Development	47,849
Selling, General and Administrative Expense	20,826

Output Variable	Value in 1000 USD
Assets	139,195
Liabilities	20,801
Expenses	68,675
Revenues	0
Stockholders Equity	118,394
Net Income	-67,061
Comprehensive Net Income	-67,172
Economic Capital Ratio	171%